Moventig® is indicated for the treatment of opioid induced constipation (OIC) in adult patients who have had an inadequate response to laxatives. It is the first oral once daily peripherally acting mu-opioid receptor antagonist (PAMORA) that selectively blocks mu-opioid receptors in the bowel, providing patients relief from opioid induced constipation (OIC) without impacting their pain control.

Marketed by Kyowa Kirin International in

  • Germany
  • UK
  • Ireland
  • Denmark
  • Finland
  • Norway
  • Sweden
  • Switzerland
  • Austria
  • Spain
  • Italy
  • Estonia
  • France
  • Netherlands